Michael Vasconcelles filed an initial statement of beneficial ownership with the SEC on November 3, 2026, reporting no securities of MacroGenics Inc held as of his October 30, 2026 triggering event date.

Key Highlights

  • Reporting person: Michael Vasconcelles, identified in the filing as a Director of MacroGenics Inc (NASDAQ:MGNX).
  • Triggering event date: October 30, 2026, the date requiring the initial beneficial ownership statement.
  • No securities held: The filing states, "No securities are beneficially owned," covering both non-derivative and derivative securities.
  • Signature: The document was signed by Beth A. Smith as attorney-in-fact on November 3, 2026.
  • Filing type: Initial statement, not an amendment, filed by one reporting person.

Vasconcelles Joins MacroGenics Board With No Initial Share Position

According to the filing, Michael Vasconcelles joined MacroGenics Inc as a Director, with October 30, 2026 designated as the date of the event requiring submission of an initial beneficial ownership statement. MacroGenics is a biopharmaceutical company listed on NASDAQ under the ticker MGNX, focused on the discovery and development of antibody-based therapeutics for cancer and other serious diseases.

The filing discloses no entries in either Table I, covering non-derivative securities beneficially owned, or Table II, covering derivative securities such as options, warrants, or convertible instruments. The remarks section of the form confirms this explicitly, stating that "No securities are beneficially owned." This means Vasconcelles reported holding no direct or indirect position in MacroGenics equity or related instruments at the time of his filing obligation arising.

The document was submitted on November 3, 2026, and was signed by Beth A. Smith acting as attorney-in-fact for Vasconcelles. The filing was made pursuant to Section 16(a) of the Securities Exchange Act of 1934, which requires directors, officers, and certain shareholders to disclose their initial holdings upon becoming subject to reporting requirements. No amendment date is listed, confirming this is an original filing.

What Was Disclosed

Michael Vasconcelles, a newly designated Director of MacroGenics Inc (NASDAQ:MGNX), disclosed through an initial beneficial ownership statement filed November 3, 2026, that he held no direct or indirect securities of the company as of October 30, 2026.